ArchPoint Investors’s Sarepta Therapeutics SRPT Stock Holding History

ArchPoint Investors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,000	Closed	-$377K	–	141
2019 Q3	$377K	Sell	5,000 -19,234	-79%	-$2.27M	0.13%	68
2019 Q2	$3.68M	Buy	24,234 +2,500	+12%	+$304K	1.16%	17
2019 Q1	$2.59M	Buy	+21,734	New	+$2.79M	0.77%	25
2017 Q4	–	Sell	-2,000	Closed	-$91K	–	159
2017 Q3	$91K	Buy	+2,000	New	+$79.9K	0.03%	113

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ArchPoint Investors's SRPT Position: Q4 2019 in Review

ArchPoint Investors sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 5,000 shares — an estimated $377K sold.

ArchPoint Investors first reported a position in SRPT in Q3 2017 and held it in 4 quarters. The position peaked at $3.68M in Q2 2019. 390 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

ArchPoint Investors reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
ArchPoint Investors sold 5,000 Sarepta Therapeutics shares in Q4 2019, an estimated $377K.
ArchPoint Investors first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 4 quarters.
ArchPoint Investors's Sarepta Therapeutics position peaked at $3.68M in Q2 2019.
390 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on ArchPoint Investors's 13F filing for Q4 2019, filed 12 Feb 2020.